<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079102</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16100408</org_study_id>
    <nct_id>NCT03079102</nct_id>
  </id_info>
  <brief_title>Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest</brief_title>
  <acronym>iNOOHCA</acronym>
  <official_title>Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cameron Dezfulian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II double blind (participants and investigator) placebo controlled randomized (1:1)
      clinical trial of inhaled nitric oxide (iNO) 20 ppm administered over 12h beginning as soon
      as possible but within 4 h of return of spontaneous circulation (ROSC) from out-of-hospital
      cardiac arrest (OHCA). Planned enrollment is 130 subjects over 24 months at University of
      Pittsburgh Medical Center (UPMC) Presbyterian and UPMC Mercy with randomization stratified in
      blocks of 8. Recruitment will be performed under exception from informed consent (EFIC) to
      facilitate early enrollment and treatment. The study will have a pre-specified safety
      analysis at the mid-point (after 1 year or 60 patients whichever occurs first). Subjects will
      be screened by members of the University of Pittsburgh post-cardiac arrest service (PCAS),
      all of whom will serve as the study co-investigators, and the Research Coordinators.
      Notification of inclusion under EFIC will be performed as soon as possible by a member of the
      study team generally to a surrogate as the subjects will be comatose after OHCA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be identified upon emergency department (ED) arrival or upon transfer from an
      outside facility and screened for enrollment by a PCAS physician as soon as possible.
      Eligible patients will have receive any required resuscitation (including central venous and
      arterial line placement, endotracheal intubation and hemodynamic resuscitation as needed)
      prior ot having baseline labs and studies performed. Subjects will then be started on study
      drug delivered via the mechanical ventilator with a concealed canister (subject, providers
      and outcome assessors blind to treatment assignment). Randomization will be performed 1:1 in
      blocks of 8 using a random number generator. A randomization list will be prepared in advance
      by the director of respiratory therapy (RT) at each site and verified by a company
      representative. These individuals (who are not part of the study team) will be unblinded and
      assure that allocation to placebo and intervention is accurate. The allocation list will
      assign study drug canisters (by barcode) to each subject in order of study ID. Treatment
      assignment will be revealed after opening a sealed opaque envelope once enrollment is
      confirmed by a physician investigator. Study drug will then be administered by RT based on
      allocation. During study drug administration hourly vital signs will be obtained and
      methemoglobin levels for safety. Study drug will be weaned off after 12h over the course of
      1h (10, 5, 4, 3, 2, 1 ppm each for 10 min) prior to discontinuation. Subjects will then
      receive standard post-resuscitation care with outcomes assessed by a blinded study team
      member (see below for outcomes).

      Additional clinical variables to be collected Demographics and baseline function. Age, sex,
      race, maximum education level, employment status, marital status, Barthel activities of daily
      living (ADL) index prior to OHCA.

      Arrest data. Location of OHCA, witnessed, bystander cardiopulmonary resuscitation (CPR),
      estimated no flow and low flow times, presenting rhythm, doses of epinephrine administered,
      shocks administered, recurrent arrest, date and time of ROSC.

      Medical comorbidities. Diabetes, hypertension, active smoking, hyperlipidemia, chronic
      obstructive pulmonary disease (COPD), hypertension, drug abuse, prior myocardial infarction,
      prior coronary artery bypass grafting (CABG), prior coronary angiography with angioplasty or
      stent, congestive heart failure (EF on last echocardiogram [ECHO] prior to OHCA), obstructive
      sleep apnea, pulmonary hypertension, calculated Charlson comorbidity index (CCI).

      Home medications. Statins, nitrates, anticoagulation, antiplatelet agents Hospital
      Interventions. Coronary angiography, percutaneous coronary intervention, CABG, mechanical
      ventilation hours and fraction of inspired oxygen (FiO2) from 0-24h after therapy start
      In-hospital medications. Alteplase, anti-epileptic medication use (valproate, phenytoin,
      lacosamide, leveteracetam), neurostimulants (methylphenidate, bromocriptine, modafinil,
      amantadine), cumulative dose of fentanyl, propofol, midazolam, cis-atracurium and vecuronium
      in at 24 (+/- 12 hours), 48 (+/- 12 hours), and 72 (+/- 12 hours) hours after therapy
      initiation

      Data Storage Subjects will be assigned a study identifier (ID) upon entry and all
      data/samples stored using that ID. Linkage to patient identifiers will be maintained in a
      secure spreadsheet and will include name, date of birth and medical record number. Clinical
      data will be entered on case report forms (source documentation) which will be stored in a
      locked filing cabinet within a locked office assigned to the study team. Deidentified
      clinical and lab data will all be subsequently entered from the case report forms into a web
      based database (REDCap) to be maintained by Dr. Dezfulian's research assistant who has prior
      experience from other studies.

      Statistical Analysis Plan Continuous data will be compared using t-tests and repeated
      measures ANOVA to compare between iNO and placebo groups at multiple times. Dichotomous
      outcomes including the primary endpoint will be compared by chi squared test. Time to
      awakening and 90d survival will be compared by log rank test of Kaplan-Meier survival plots.
      All tests will be two tailed with unadjusted p&lt;0.05 considered significant. In the event of a
      differential distribution of baseline variables strongly associated with outcome (univariate
      OR &gt;2), dichotomous outcomes will be adjusted for these baseline variables.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">November 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 1:1 to either placebo or active study drug (iNO). This will be stratified within blocks of 8 subjects at each center.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Gas canisters will be marked with a bar code which will be recorded by the study coordinator and available to the study team. Only the respiratory therapy directors will be aware of the canister content (placebo vs. active drug). Treatment assignment will be revealed upon opening a sealed opaque envelope after enrollment has been confirmed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death or significant neurological or cardiac impairment</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>Composite of in-hospital death; OR unfavorable discharge location defined as a skilled nursing facility (SNF), long term acute care (LTAC) or hospice; OR New York Heart Association (NYHA) class III/IV heart failure at the time of discharge.*
*In the setting of pre-existing heart failure there must be at least a 1 class decrement (eg III -&gt; IV). If patient was previously housed in a &quot;unfavorable&quot; destination there must be a 1 point decrement (eg from SNF to LTAC or LTAC to hospice). Subjects with pre-existing NYHA IV symptoms or living in hospice are excluded from meeting the respective outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>Patient declared dead at designated time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>Patient declared dead at designated time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>90 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>Patient declared dead at designated time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category (CPC)</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>CPC is a standardized scale from 1-5 describing neurological and functional outcome. CPC will be dichotomized as favorable (1, 2) or unfavorable (3-5) at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category - extended (CPC-E)</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>CPC-E as a continuous measure (1-5) across each of 6 categories within 48h of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category - extended (CPC-E)</measure>
    <time_frame>30 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>CPC-E as a continuous measure (1-5) across each of 4 categories at designated time assuming patient is discharged from hospital (if subject is hospitalized the 6 category scale designated above will be used)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category - extended (CPC-E)</measure>
    <time_frame>90 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>CPC-E as a continuous measure (1-5) across each of 4 categories at designated time assuming patient is discharged from hospital (if subject is hospitalized the 6 category scale designated above will be used)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category (CPC)</measure>
    <time_frame>30 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>CPC dichotomized as favorable (1, 2) or unfavorable (3-5) at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral performance category (CPC)</measure>
    <time_frame>90 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>CPC dichotomized as favorable (1, 2) or unfavorable (3-5) at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>mRS dichotomized as favorable (0-3) or unfavorable (4-6) at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>30 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>mRS dichotomized as favorable (0-3) or unfavorable (4-6) at 30 days post-cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>90 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>mRS dichotomized as favorable (0-3) or unfavorable (4-6) at 90 days post-cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge destination</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>Location to which patient will be discharged dichotomized as favorable (home or inpatient rehabilitation) or unfavorable (skilled nursing facility, long term acute care, hospice or morgue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (activities of daily living)</measure>
    <time_frame>Hospital discharge (+/- 3 days)</time_frame>
    <description>Barthel Index of Independence in Activities of Daily Living scored as a continuous 0-100 at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (activities of daily living)</measure>
    <time_frame>30 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>Barthel Index of Independence in Activities of Daily Living scored as a continuous 0-100 at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (activities of daily living)</measure>
    <time_frame>90 days after cardiac arrest (+/- 3 days)</time_frame>
    <description>Barthel Index of Independence in Activities of Daily Living scored as a continuous 0-100 at designated time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to awakening</measure>
    <time_frame>Within 4 days of cardiac arrest</time_frame>
    <description>Time in hours until subject is noted to follow commands. Subjects exceeding 96 hours of coma and those that die without awakening will be designated as 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methemoglobin level</measure>
    <time_frame>Prior to study drug</time_frame>
    <description>Methemoglobin content as proportion (%) of total hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methemoglobin level</measure>
    <time_frame>6 hours after study drug initiated</time_frame>
    <description>Methemoglobin content as proportion (%) of total hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methemoglobin level</measure>
    <time_frame>12 hours after study drug initiated</time_frame>
    <description>Methemoglobin content as proportion (%) of total hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHOcardiogram</measure>
    <time_frame>Prior to study drug</time_frame>
    <description>Measurement of left ventricular ejection fraction, tricuspid regurgitant velocity and trans-anular pulmonic valve excursion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHOcardiogram</measure>
    <time_frame>12 hours after study drug initiated</time_frame>
    <description>Measurement of left ventricular ejection fraction, tricuspid regurgitant velocity and trans-anular pulmonic valve excursion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia</measure>
    <time_frame>Prior to study drug</time_frame>
    <description>Reactive hyperemia (increase in blood flow from baseline) measured by laser speckle contrast imaging before and after a 1 and 5 min blood pressure cuff occlusion (20 mm Hg above systolic blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia</measure>
    <time_frame>12 hours after study drug</time_frame>
    <description>Reactive hyperemia (increase in blood flow from baseline) measured by laser speckle contrast imaging before and after a 1 and 5 min blood pressure cuff occlusion (20 mm Hg above systolic blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Hourly from 0 - 12 hours of study drug</time_frame>
    <description>Measured by arterial line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Hourly from 0 - 12 hours of study drug</time_frame>
    <description>Measured by arterial line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Hourly from 0 - 12 hours of study drug</time_frame>
    <description>Calculated from continuous telemetry by monitor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Heart Arrest, Out-Of-Hospital</condition>
  <arm_group>
    <arm_group_label>inhaled nitric oxide (iNO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nitrogen carrier gas delivered by identical system with similar dose/taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <description>An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.</description>
    <arm_group_label>inhaled nitric oxide (iNO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrogen</intervention_name>
    <description>Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intubated and comatose adult (&gt;18 yo) resuscitated from out-of-hospital cardiac arrest
             (OHCA)*

             *Cardiac arrest within an emergency department or outpatient medical center will be
             included). OHCA includes Emergency Medical Service (EMS) witnessed cardiac arrest.

          -  Return of spontaneous circulation (ROSC) within 40 min of CPR initiation

          -  Full Outline of Unresponsiveness (FOUR) Brainstem score â‰¥ 2 (i.e. patient must have
             pupil OR corneal reflex at the time of ED presentation or within 1h if
             sedation/neuromuscular blockade clouds the picture)

        Exclusion Criteria:

          -  Traumatic etiology of OHCA

          -  Prisoner

          -  Known pregnancy (beta-human chorionic gonadotropin screening is NOT REQUIRED for
             enrollment in women of appropriate age)

          -  Hemodynamic instability defined as &gt;1 recurrent arrest prior to enrollment OR
             inability to maintain mean arterial blood pressure (MAP) &gt; 65 using vasopressors and
             inotropes (ie actively up titrating medications or giving fluid bolus)

          -  Head CT grey-white ratio &lt; 1.2; Head CT is NOT REQUIRED prior to enrollment

          -  Fixed and dilated pupils without another explanation

          -  Known intracranial hemorrhage or acute cerebral infarction; Head CT is NOT REQUIRED
             prior to enrollment

          -  Malignant EEG upon presentation defined as: myoclonic status epilepticus,
             non-convulsive status epilepticus, generalized periodic epileptiform discharges. EEG
             screening is NOT REQUIRED prior to enrollment

          -  ROSC &gt;3h from time of ED arrival (treatment allocation must be within 4h so anything
             that will prevent this is reason for exclusion)

          -  Alert and interactive patient with minimal evidence of neurologic injury

          -  Plan to extubate within 12 hours

          -  Post-cardiac arrest service (PCAS) physician opinion that patient will die with &gt;95%
             likelihood. This may be based on:

               -  Multiple medical comorbidities

               -  Late discovery of don not resuscitate (DNR) or advanced directive

               -  Terminal diagnosis (other than OHCA; may have caused OHCA)

               -  Clinical judgement based on current exam and data

          -  Patient is known to be taking phosphodiesterase type 5 (PDE5) inhibitors, soluble
             guanylyl cyclase (sGC) stimulator, or has a known diagnosis of Chronic thromboembolic
             pulmonary hypertension (CTEPH), pulmonary hypertension (PAH), or erectile dysfunction

          -  Known enrollment in another acute interventional study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cameron Dezfulian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Critical Care Medicine and Clinical and Translational Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara DiFiore, BA</last_name>
    <phone>412-864-2284</phone>
    <email>difioresm@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Krehel, BS</last_name>
    <phone>570-561-3132</phone>
    <email>NMK54@pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara DiFiore, BA</last_name>
      <phone>412-864-2284</phone>
      <email>difioresm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Cameron Dezfulian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Rittenberger, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clifton Callaway, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Elmer, MD, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank X Guyette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Frisch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ankur Doshi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Molyneaux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Weissman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masashi Okubo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick M Krehel, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Surya Sharma, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Mercy Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Difiore, BA</last_name>
      <phone>412-864-2284</phone>
      <email>difioresm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Cameron Dezfulian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ankur Doshi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Rittenberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clifton Callaway, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Elmer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis Guyette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Sawyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Weissman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Frisch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Masashi Okubo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nick M Krehel, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Surya Sharma, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Cameron Dezfulian</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

